Evaluation of the Efficacy and Safety of CollaSel PRO® Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Demir-Dora, Devrim et al.·Journal of clinical medicine·2025·
RPEP-106862025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Evaluation of the Efficacy and Safety of CollaSel PRO® Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Published In:
Journal of clinical medicine, 14(11) (2025)
Database ID:
RPEP-10686

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10686·https://rethinkpeptides.com/research/RPEP-10686

APA

Demir-Dora, Devrim; Tuna, Serpil; Kurtoglu, Emel Dogan; Gursoy, Savas; Balci, Nilufer; Tezman, Selim; Erenmemisoglu, Aydin. (2025). Evaluation of the Efficacy and Safety of CollaSel PRO® Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.. Journal of clinical medicine, 14(11). https://doi.org/10.3390/jcm14113655

MLA

Demir-Dora, Devrim, et al. "Evaluation of the Efficacy and Safety of CollaSel PRO® Type I and Type III Hydrolyzed Collagen Peptides in the Treatment of Osteoarthritis: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.." Journal of clinical medicine, 2025. https://doi.org/10.3390/jcm14113655

RethinkPeptides

RethinkPeptides Research Database. "Evaluation of the Efficacy and Safety of CollaSel PRO® Type ..." RPEP-10686. Retrieved from https://rethinkpeptides.com/research/demir-dora-2025-evaluation-of-the-efficacy

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.